当前位置：药药网 / 医药文献 /临床试验研究设计终点和生物标志物药物安全性(本栏目收费,不能显示细节,电话13136136841)
关键字：
类型：
下载页码(大于等于0,小于611)：
临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
Breast cancer biomarkers,332–337
332 337
gene array as prognostic factor,267–268
267 268
health-related quality of life,397–398
397 398
Contract research organization (CRO),445,447
445 447
Council of International Organizations of Medical Sciences (CIOMS)adverse event classification,426
426
C-reactive protein (CRP)biology,345–346
345 346
biomarker applications atherosclerosis,349–351
349 351
inflammatory bowel disease levels,341
341
Crohn’s disease C-reactive protein levels,341
341
health-related quality of life,404–405
404 405
CTCAE dictionary adverse event severity grading,442–443
442 443
CTD see Common Technical Document Cumulative toxicity basis of exclusion,74–76
74 76
Cytokines see also specific cytokines classification,476–477
476 477
mechanism of action considerations in diseases with immune component,476–478
476 478
modulation of immune system,483–484
483 484
timing of questionnaires,386–387
386 387
Hematological cancers see also specific cancers acute lymphocytic leukemia,284–287
284 287
acute myeloid leukemia,289–291
289 291
acute promyelocytic leukemia,291–292
291 292
chronic lymphocytic leukemia,287–288
287 288
chronic myeloid leukemia,293–294
293 294